BMAL1 and neuroblastoma: These two groups of studies showed that MYC suppressed BMAL1 across a wide range of cancers, including osteosarcoma, neuroblastoma, hepatocellular carcinoma, Burkitt’s lymphoma, and T cell acute lymphoblastic leukemia [34,35,36,37,38].